AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24253247 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir plus ritonavir (ATV/r) with abacavir/lamivudine (ABC/3TC)
Number of subjects: 1857
Study 24253247 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir plus ritonavir (ATV/r) with tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 1857
Study 24253247 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) with abacavir/lamivudine (ABC/3TC)
Number of subjects: 1857
Study 24253247 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) with tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 1857
Study 24253247 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir plus ritonavir (ATV/r)
Number of subjects: 1857
Study 24253247 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 1857
Study 22118480 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic stable intramedullary nailing (ESIN)
Number of subjects: 60
Study 22118480 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 60
Study 22118480 — intervention group
Group type: EXPERIMENTAL
Intervention: ESIN
Number of subjects: 60
Study 19117055 — intervention group
Group type: COMPARATOR
Intervention: Low seropositivity for T. vaginalis (21.5% of cases, 24.8% of controls)
Number of subjects: 18882
Study 19117055 — intervention group
Group type: COMPARATOR
Intervention: High seropositivity for T. vaginalis (15.2% of cases, 15.0% of controls)
Number of subjects: 18882
Study 17329991 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose simvastatin
Number of subjects: 86
Study 17329991 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 86
Study 17329991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 15137184 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped counseling intervention
Number of subjects: 32
Study 15137184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 11800440 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica coating + silanating (CO)
Number of subjects: 120
Study 11800440 — intervention group
Group type: EXPERIMENTAL
Intervention: Roughening with a silicon carbide bur (SC)
Number of subjects: 120
Study 11800440 — intervention group
Group type: COMPARATOR
Intervention: Hydrofluoric acid etching for 15 s + silanating (HF)
Number of subjects: 120
Study 11800440 — intervention group
Group type: COMPARATOR
Intervention: Without treatment (WT)
Number of subjects: 120
Study 9890203 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 0.5 microg/min
Number of subjects: 22
Study 9890203 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 1.0 microg/min
Number of subjects: 22
Study 9890203 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol, acetylcholine, and nitroglycerin (dosage not specified)
Number of subjects: 22
Study 7905097 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow infusion after a 10 day course of antithymocyte globulin, 5 days post-transplantation.
Number of subjects: 25
Study 7905097 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what treatment they received).
Number of subjects: 25
Study 7905097 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow infusion group.
Number of subjects: 25
Study 7905097 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 25
Study 3191090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% (w/v) chlorhexidine gluconate
Number of subjects: 324
Study 3191090 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 324
Study 3191090 — intervention group
Group type: COMPARATOR
Intervention: No irrigation
Number of subjects: 324
Study 29597051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery pulsatility index (PAPi)
Number of subjects: 190
Study 27048197 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based monitoring
Number of subjects: 272
Study 27048197 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO-based monitoring
Number of subjects: 272
Study 27048197 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 272
Study 25700006 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention tailored to drinking motives, profile-specific online training for 4 weeks
Number of subjects: 124
Study 25700006 — intervention group
Group type: COMPARATOR
Intervention: Profile-specific feedback only (Control)
Number of subjects: 124
Study 23917673 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (5 mg bid)
Number of subjects: 10
Study 23917673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20945819 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser vaporization plus Pidotimod and vitamin C for 2 1/2 months
Number of subjects: 62
Study 20945819 — intervention group
Group type: COMPARATOR
Intervention: Laser vaporization alone
Number of subjects: 62
Study 19035101 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE + HITT therapy
Number of subjects: 65
Study 19035101 — intervention group
Group type: COMPARATOR
Intervention: TACE + PEI only therapy
Number of subjects: 65
Study 17234829 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing intervention
Number of subjects: 2802
Study 17234829 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory intervention
Number of subjects: 2802
Study 17234829 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning intervention
Number of subjects: 2802
Study 17234829 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 2802
Study 12776028 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-stent
Number of subjects: 145
Study 12776028 — intervention group
Group type: COMPARATOR
Intervention: Wallstent
Number of subjects: 145
Study 11032201 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced back care plus manual therapy
Number of subjects: 191
Study 11032201 — intervention group
Group type: COMPARATOR
Intervention: Enhanced back care
Number of subjects: 191
Study 10072995 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-MIBI SPECT imaging
Number of subjects: 74
Study 8330997 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 Gy twice daily, 5 days a week, with total brain treatment to 32.0 Gy and boost doses escalating from 16.0 Gy to 42.40 Gy.
Number of subjects: 0
Study 8330997 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled primary tumors, non-lung primaries, and solitary metastasis.
Number of subjects: 0
Study 3299287 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine insulin (group A)
Number of subjects: 30
Study 3299287 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (group C)
Number of subjects: 30
Study 3299287 — intervention group
Group type: EXPERIMENTAL
Intervention: Good metabolic control (group B)
Number of subjects: 30
Study 3299287 — intervention group
Group type: COMPARATOR
Intervention: Good metabolic control (group D)
Number of subjects: 30
Study 3299287 — intervention group
Group type: COMPARATOR
Intervention: Control group (group K)
Number of subjects: 30
Study 29265791 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-augmented RAGT
Number of subjects: 20
Study 29265791 — intervention group
Group type: COMPARATOR
Intervention: Standard RAGT
Number of subjects: 20
Study 29265791 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC
Number of subjects: 20
Study 27481306 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach plus $5 incentive
Number of subjects: 8656
Study 27481306 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach plus $10 incentive
Number of subjects: 8656
Study 27481306 — intervention group
Group type: COMPARATOR
Intervention: Outreach (no incentive)
Number of subjects: 8656
Study 27481306 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach plus any financial incentive
Number of subjects: 8656
Study 24909254 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral mother training (BMT)
Number of subjects: 73
Study 24909254 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal self-instruction to the children (VSI)
Number of subjects: 73
Study 24909254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 73
Study 24909254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 22230826 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care intervention
Number of subjects: 180
Study 22230826 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study 20397458 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-needling plus Tuina relaxing
Number of subjects: 98
Study 20397458 — intervention group
Group type: COMPARATOR
Intervention: Hormone block therapy and drug medication
Number of subjects: 98
Study 18680246 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dexrabeprazole daily
Number of subjects: 0
Study 18680246 — intervention group
Group type: COMPARATOR
Intervention: 20 mg rabeprazole daily
Number of subjects: 0
Study 16185308 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin treatment (nasal inhalation, twice daily for 13 weeks)
Number of subjects: 59
Study 16185308 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (nasal inhalation, twice daily for 13 weeks)
Number of subjects: 59
Study 14986908 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education program and supervised tooth brushing with fluoridated toothpaste (1100 ppm F‐) in test group (n = 258)
Number of subjects: 514
Study 14986908 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 256) with no oral health education and no supervised tooth brushing
Number of subjects: 514
Study 14986908 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of children in the test group
Number of subjects: 514
Study 10634838 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophic feeding (0.5‐1 ml/h) along with parenteral nutrition
Number of subjects: 100
Study 10634838 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition alone
Number of subjects: 100
Study 8803511 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous running at 95 and 105% of vMTT
Number of subjects: 7
Study 8803511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent running at 95 and 105% of vMTT
Number of subjects: 7
Study 1466894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary application of 226Ra plus external radiotherapy
Number of subjects: 2
Study 1466894 — intervention group
Group type: COMPARATOR
Intervention: 252Cf, 226Ra and extended radiotherapy
Number of subjects: 2
Study 6489151 — intervention group
Group type: EXPERIMENTAL
Intervention: High methadone dose increase to 60 mg in week 4, then gradual reduction to 30 mg by week 10.
Number of subjects: 26
Study 6489151 — intervention group
Group type: COMPARATOR
Intervention: Constant 30 mg methadone dose through treatment week 10.
Number of subjects: 26
Study 6489151 — intervention group
Group type: EXPERIMENTAL
Intervention: High methadone dose increase group (experimental)
Number of subjects: 26
Study 6489151 — intervention group
Group type: COMPARATOR
Intervention: Constant 30 mg methadone dose group (control)
Number of subjects: 26
Study 6489151 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 30157839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment educational programme followed by treatment as usual
Number of subjects: 93
Study 30157839 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 93
Study 27155741 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictilisib (340 mg in part 1; 260 mg in part 2) plus fulvestrant 500 mg
Number of subjects: 229
Study 27155741 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant 500 mg
Number of subjects: 229
Study 27155741 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictilisib (340 mg in part 1; 260 mg in part 2)
Number of subjects: 229
Study 27155741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 24581309 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative exploration of psychological distress management strategies among mothers
Number of subjects: 22
Study 24581309 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for psychological distress using the GHQ-12
Number of subjects: 22
Study 24581309 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to address gender inequity and improve access to perinatal healthcare
Number of subjects: 22
Study 22416676 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Interruption (TI) arm
Number of subjects: 54
Study 22416676 — intervention group
Group type: COMPARATOR
Intervention: Treatment Continuation (TC) arm
Number of subjects: 54
Study 22416676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 54
Study 20399687 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 T MRA
Number of subjects: 19
Study 20399687 — intervention group
Group type: COMPARATOR
Intervention: 1.5 T MRA
Number of subjects: 19
Study 18826999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 1766
Study 18826999 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 1766
Study 18826999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1766
Study 15955382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg/day)
Number of subjects: 91
Study 15955382 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 91
Study 12216432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral continuous 17-beta estradiol and norethindrone acetate
Number of subjects: 50
Study 12216432 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal cyclic 17-beta estradiol and norethindrone acetate
Number of subjects: 50
Study 10215734 — intervention group
Group type: EXPERIMENTAL
Intervention: LCM (lansoprazole, clarithromycin, metronidazole)
Number of subjects: 168
Study 10215734 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC (lansoprazole, amoxycillin, clarithromycin)
Number of subjects: 168
Study 10215734 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM (lansoprazole, clarithromycin, amoxycillin)
Number of subjects: 168
Study 7887385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 10 or 20 mg/day
Number of subjects: 241
Study 7887385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 241
Study 2532927 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (SF 86-327, Lamisil) 250 mg daily for 6 months (finger-nail) and 12 months (toe-nail)
Number of subjects: 30
Study 2532927 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (SF 86-327, Lamisil) 250 mg daily
Number of subjects: 30
Study 57520 — intervention group
Group type: EXPERIMENTAL
Intervention: WRL 105 strain live influenza vaccine
Number of subjects: 45
Study 57520 — intervention group
Group type: COMPARATOR
Intervention: Alice strain live influenza vaccine
Number of subjects: 45
Study 29982714 — intervention group
Group type: EXPERIMENTAL
Intervention: First-year eGFR variability measured by coefficient of variation (eGFR-CV)
Number of subjects: 5092
Study 29982714 — intervention group
Group type: EXPERIMENTAL
Intervention: First-year eGFR variability measured by percent change (eGFR-PC)
Number of subjects: 5092
Study 29982714 — intervention group
Group type: EXPERIMENTAL
Intervention: First-year eGFR variability measured by absolute difference (eGFR-AD)
Number of subjects: 5092
Study 29982714 — intervention group
Group type: EXPERIMENTAL
Intervention: First-year eGFR variability measured by slope (eGFR-slope)
Number of subjects: 5092
Study 29982714 — intervention group
Group type: EXPERIMENTAL
Intervention: First-year eGFR variability measured by area under the curve (eGFR-AUC)
Number of subjects: 5092
Study 29982714 — intervention group
Group type: EXPERIMENTAL
Intervention: High quartile of eGFR-CV with declining quartiles of other eGFR change scales
Number of subjects: 5092
Study 28931617 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hyperoxia (NBO) treatment (100% O2) in rats during middle cerebral artery occlusion.
Number of subjects: 0
Study 28931617 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hyperoxia (NBO) treatment in patients with AIS receiving intravenous tPA thrombolysis.
Number of subjects: 0
Study 28931617 — intervention group
Group type: COMPARATOR
Intervention: Control group (normoxia, 21% O2) in rats during middle cerebral artery occlusion.
Number of subjects: 0
Study 28931617 — intervention group
Group type: COMPARATOR
Intervention: Control group (room air) in patients with AIS.
Number of subjects: 0
Study 26241428 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal supervised pelvic floor muscle training
Number of subjects: 282
Study 26241428 — intervention group
Group type: COMPARATOR
Intervention: Written instructions on pelvic floor exercises (Control)
Number of subjects: 282
Study 26241428 — intervention group
Group type: COMPARATOR
Intervention: Both groups received written instructions about how to perform exercises at home
Number of subjects: 282
Study 23494931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil plus testosterone gel (n=70)
Number of subjects: 140
Study 23494931 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil plus placebo gel (n=70)
Number of subjects: 140
Study 21081772 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint stimulation group (ASG; bilateral transcutaneous electrical acupoint stimulation at Neiguan, PC‐6)
Number of subjects: 30
Study 21081772 — intervention group
Group type: COMPARATOR
Intervention: Conventional promotility drug treatment group (DTG; metoclopramide, cisapride, erythromycin)
Number of subjects: 30
Study 21081772 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint stimulation
Number of subjects: 30
Study 21081772 — intervention group
Group type: COMPARATOR
Intervention: Conventional promotility drugs
Number of subjects: 30
Study 19689171 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing (PoCT) in intervention practices using devices such as Siemens DCA 2000 for HbA1c and urine ACR, Cholestech LDX for lipids, and Roche CoaguChek S for INR.
Number of subjects: 4968
Study 19689171 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial training workshops for device operators.
Number of subjects: 4968
Study 19689171 — intervention group
Group type: EXPERIMENTAL
Intervention: Refresher training workshops for device operators.
Number of subjects: 4968
Study 19689171 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Trial satisfaction questionnaire for device operators.
Number of subjects: 4968
Study 19689171 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction survey completed by device operators after initial training workshops.
Number of subjects: 4968
Study 19689171 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PoCT training resources and workshop evaluation.
Number of subjects: 4968
Study 16949830 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted reperfusion (LD group)
Number of subjects: 40
Study 16949830 — intervention group
Group type: COMPARATOR
Intervention: Whole blood reperfusion (Control group)
Number of subjects: 40
Study 10818079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasidotril (100 mg twice daily for 6 weeks)
Number of subjects: 57
Study 10818079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 8895272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 48
Study 8895272 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.625 mg
Number of subjects: 48
Study 8895272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 48
Study 2066846 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (0.2 mg/kg)
Number of subjects: 35
Study 2066846 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.2 mg/kg)
Number of subjects: 35
Study 6133103 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice on cholesterol-lowering diet, smoking cessation, weight control, exercise, and treatment of hypertension.
Number of subjects: 18210
Study 30625070 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab (10 mg intravenous loading bolus, followed by 10 mg daily subcutaneously)
Number of subjects: 145
Study 30625070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 30625070 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 145
Study 29077240 — intervention group
Group type: COMPARATOR
Intervention: Live Tissue (LT)
Number of subjects: 559
Study 29077240 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic Training Models (STM)
Number of subjects: 559
Study 26731754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 147
Study 26731754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 24215845 — intervention group
Group type: EXPERIMENTAL
Intervention: Brostallicin 10mg/m²
Number of subjects: 118
Study 24215845 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 75mg/m²
Number of subjects: 118
Study 22439822 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion powder (OP)
Number of subjects: 16
Study 22439822 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple peel powder (AP)
Number of subjects: 16
Study 22439822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of apple peel and onion powder enriched applesauce (MP)
Number of subjects: 16
Study 22439822 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OP to AP
Number of subjects: 16
Study 22439822 — intervention group
Group type: COMPARATOR
Intervention: Gender-related differences
Number of subjects: 16
Study 20421444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus Lcr35
Number of subjects: 9
Study 20421444 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli Nissle
Number of subjects: 9
Study 20421444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 17920475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated stem
Number of subjects: 20
Study 17920475 — intervention group
Group type: COMPARATOR
Intervention: Standard blasted stem
Number of subjects: 20
Study 17920475 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stems
Number of subjects: 20